据《华尔街日报》报道，埃利奥特增持生命科学公司Bio-Rad Labs的大量股份

2026-05-18 11:37

Activist Elliott Investment Management has built a sizable stake in Bio-Rad Laboratories (BIO) and plans to push the supplier of life-science tools and diagnostics products to boost its underperforming stock price, the WSJ reported.
Elliott is also a large investor in Sartorius (SARTF), the German supplier of pharmaceutical and laboratory equipment that Bio-Rad (BIO) has a strategic investment in, the report said. Sartorius serves makers of biologic drugs, which now dominate pharmaceuticals.
The exact size of Elliott's shareholding in Bio-Rad or Sartorius was not disclosed ‌in ⁠the report.
The U.S. activist, which has been quite active in the healthcare sector, believes Sartorius is a high-quality business with strong growth potential, the report said.
Bio-Rad (BIO) recently lowered its ⁠2026 revenue growth outlook after posting a first-quarter net loss of $527 million. The company attributed the change in the ⁠fair market value of its Sartorius AG investment

More on Bio-Rad Laboratories, Inc., Sartorius Aktiengesellschaft

Bio-Rad Laboratories, Inc. (BIO) Q1 2026 Earnings Call Transcript
Sartorius Aktiengesellschaft 2026 Q1 - Results - Earnings Call Presentation
Sartorius Aktiengesellschaft (SOAGY) Q1 2026 Earnings Call Transcript
Bio-Rad outlines 2026 currency-neutral revenue growth of -3% to +0.5% amid Middle East disruption
Bio-Rad Laboratories, Inc. Non-GAAP EPS of $1.89 misses by $0.10, revenue of $592.1M beats by $3.24M